ArticleCureus2025
Evaluation of Mediastinal Lymphadenopathy in Patients With Non-small Cell Lung Cancer Using Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Lung cancer is the leading cause of cancer-related deaths worldwide. Accurate staging of mediastinal lymphadenopathy is crucial, particularly in tuberculosis-endemic regions where benign causes can mimic malignancy. Imaging modalities like computed tomography (CT) and positron emission tomography (PET) scans detect lymph node enlargement but lack specificity. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive technique that enables real-time sampling for histopathological diagnosis. This study evaluates the role of EBUS-TBNA in diagnosing enlarged mediastinal lymph nodes in non-small cell lung cancer (NSCLC) patients and its impact on staging. Methods A cross-sectional study was conducted at a tertiary care center in India from May 2023 to August 2024. Thirty NSCLC patients with mediastinal lymphadenopathy (≥10 mm) underwent EBUS-TBNA for histopathological evaluation. Patients with sub-centimetric nodes or severe comorbidities were excluded. CT and PET scans and EBUS findings were analyzed for malignancy, granulomas, or benign conditions. Results Among the 30 patients, 25 (83.33%) were male, with a mean age of 59.09±9.95 years. Cough was the most common symptom, affecting 24 patients (80%). A total of 67 lymph nodes were sampled using EBUS-TBNA, revealing malignancy in 57 (85.07%), tuberculosis in two (2.99%), and benign findings in eight (11.94%). Among the 54 18F-fluorodeoxyglucose (FDG)-avid lymph nodes, 44 (81.48%) were malignant, two (3.7%) had tuberculosis, and eight (14.81%) were benign. EBUS-TBNA modified nodal staging in five cases (16.67%), resulting in downstaging for four patients (13.33%) and upstaging for one patient (3.33%). No complications were observed. Conclusion EBUS-TBNA is a valuable tool for diagnosing and staging NSCLC, reducing misclassification in tuberculosis-endemic regions. It enhances accuracy by distinguishing malignancy from benign conditions, emphasizing the need for histopathological confirmation. Integrating EBUS-TBNA with imaging can optimize lung cancer management and treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.